Vitari Alberto C, Thastrup Jacob, Rafiqi Fatema H, Deak Maria, Morrice Nick A, Karlsson Håkan K R, Alessi Dario R
MRC Protein Phosphorylation Unit, School of Life Sciences, MSI/WTB complex, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, UK.
Biochem J. 2006 Jul 1;397(1):223-31. doi: 10.1042/BJ20060220.
The SPAK (STE20/SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress-responsive kinase-1) kinases interact and phosphorylate NKCC1 (Na+-K+-2Cl- co-transporter-1), leading to its activation. Recent studies indicated that SPAK and OSR1 are phosphorylated and activated by the WNK1 [with no K (lysine) protein kinase-1] and WNK4, genes mutated in humans affected by Gordon's hypertension syndrome. In the present study, we have identified three residues in NKCC1 (Thr175/Thr179/Thr184 in shark or Thr203/Thr207/Thr212 in human) that are phosphorylated by SPAK and OSR1, and have developed a peptide substrate, CATCHtide (cation chloride co-transporter peptide substrate), to assess SPAK and OSR1 activity. Exposure of HEK-293 (human embryonic kidney) cells to osmotic stress, which leads to phosphorylation and activation of NKCC1, increased phosphorylation of NKCC1 at the sites targeted by SPAK/OSR1. The residues on NKCC1, phosphorylated by SPAK/OSR1, are conserved in other cation co-transporters, such as the Na+-Cl- co-transporter, the target of thiazide drugs that lower blood pressure in humans with Gordon's syndrome. Furthermore, we characterize the properties of a 92-residue CCT (conserved C-terminal) domain on SPAK and OSR1 that interacts with an RFXV (Arg-Phe-Xaa-Val) motif present in the substrate NKCC1 and its activators WNK1/WNK4. A peptide containing the RFXV motif interacts with nanomolar affinity with the CCT domains of SPAK/OSR1 and can be utilized to affinity-purify SPAK and OSR1 from cell extracts. Mutation of the arginine, phenylalanine or valine residue within this peptide abolishes binding to SPAK/OSR1. We have identified specific residues within the CCT domain that are required for interaction with the RFXV motif and have demonstrated that mutation of these in OSR1 inhibited phosphorylation of NKCC1, but not of CATCHtide which does not possess an RFXV motif. We establish that an intact CCT domain is required for WNK1 to efficiently phosphorylate and activate OSR1. These data establish that the CCT domain functions as a multipurpose docking site, enabling SPAK/OSR1 to interact with substrates (NKCC1) and activators (WNK1/WNK4).
SPAK(STE20/SPS1相关富含脯氨酸/丙氨酸激酶)和OSR1(氧化应激反应激酶-1)激酶相互作用并磷酸化NKCC1(钠-钾-2氯协同转运蛋白-1),从而使其激活。最近的研究表明,SPAK和OSR1可被WNK1(无赖氨酸蛋白激酶-1)和WNK4磷酸化并激活,在受戈登高血压综合征影响的人类中,这两个基因发生了突变。在本研究中,我们确定了NKCC1中的三个残基(鲨鱼中的Thr175/Thr179/Thr184或人类中的Thr203/Thr207/Thr212)可被SPAK和OSR1磷酸化,并开发了一种肽底物CATCHtide(阳离子氯协同转运蛋白肽底物)来评估SPAK和OSR1的活性。将HEK-293(人类胚胎肾)细胞暴露于渗透应激下,这会导致NKCC1磷酸化并激活,增加了SPAK/OSR1靶向位点处NKCC1的磷酸化。NKCC1上被SPAK/OSR1磷酸化的残基在其他阳离子协同转运蛋白中是保守的,例如钠-氯协同转运蛋白,它是噻嗪类药物的作用靶点,这类药物可降低患有戈登综合征的人类的血压。此外,我们还表征了SPAK和OSR1上一个92个残基的CCT(保守C末端)结构域的特性,该结构域与底物NKCC1及其激活剂WNK1/WNK4中存在的RFXV(精氨酸-苯丙氨酸-Xaa-缬氨酸)基序相互作用。含有RFXV基序的肽以纳摩尔亲和力与SPAK/OSR1的CCT结构域相互作用,可用于从细胞提取物中亲和纯化SPAK和OSR1。该肽内精氨酸、苯丙氨酸或缬氨酸残基的突变会消除与SPAK/OSR1的结合。我们确定了CCT结构域内与RFXV基序相互作用所需的特定残基,并证明OSR1中这些残基的突变会抑制NKCC1的磷酸化,但不会抑制不具有RFXV基序的CATCHtide的磷酸化。我们证实完整的CCT结构域是WNK1有效磷酸化并激活OSR1所必需的。这些数据表明CCT结构域作为一个多功能对接位点,使SPAK/OSR1能够与底物(NKCC1)和激活剂(WNK1/WNK4)相互作用。